Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997993417> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W1997993417 endingPage "162" @default.
- W1997993417 startingPage "162" @default.
- W1997993417 abstract "Cisplatin is the key systemic chemotherapeutic agent used for bladder cancer, but chemoresistance is a major clinical problem. The transcription factor nuclear factor erythroid 2–related factor 2 (Nrf2) regulates various critical cellular processes, including cellular antioxidant response, cellular detoxification, and drug uptake/efflux. These processes, and the expression of multiple Nrf2 target genes, have been found to be associated with bladder cancer prognosis and chemotherapy resistance. We, therefore, investigated whether Nrf2 might regulate cisplatin resistance in bladder cancer.We first used bladder cancer cell lines, including a cisplatin-resistant RT112 subline (RT112-CP), to investigate Nrf2 expression and activation and its association with cisplatin response. We then undertook immunohistochemical analysis of a tissue microarray of archival bladder cancer radical cystectomy specimens to test the relevance of clinical Nrf2 expression to outcomes following either neoadjuvant chemotherapy and cystectomy or cystectomy alone.Bladder cancer cell lines showed variable Nrf2 expression. Nrf2 expression was greater in RT112-CP cisplatin-resistant cells compared with that in parental RT112 cells. Nrf2 overexpression was functional in this model as it was associated with increased antioxidant response element reporter construct activity, Nrf2 target gene expression (metallothionein and glutathione reductase), and basal glutathione levels. Cisplatin resistance was associated with Nrf2 expression, and in RT112-CP cells, its depletion partially restored cisplatin sensitivity. We demonstrated increased cytoplasmic or nuclear Nrf2 expression or both in 32% of clinical bladder cancer samples compared with that in normal tissue samples. Expression of Nrf2 in bladder cancer following radical cystectomy was associated with unfavorable overall (median = 0.65 vs. 2.11 y, P = 0.045), bladder cancer–specific, and recurrence-free survival in those patients who also received neoadjuvant cisplatin-based chemotherapy but not in those treated with cystectomy alone.Nrf2 overexpression in bladder cancer is associated with clinically relevant cisplatin resistance that is reversible in experimental models and should now be tested in prospective studies." @default.
- W1997993417 created "2016-06-24" @default.
- W1997993417 creator A5021521447 @default.
- W1997993417 creator A5028675951 @default.
- W1997993417 creator A5042006413 @default.
- W1997993417 creator A5056617646 @default.
- W1997993417 creator A5067312115 @default.
- W1997993417 date "2006-11-01" @default.
- W1997993417 modified "2023-09-23" @default.
- W1997993417 title "533 POSTER RTA 401 (CDDO) and RTA 402 (CDDO-Me), promising new anti-cancer agents that also prevent oral mucositis" @default.
- W1997993417 doi "https://doi.org/10.1016/s1359-6349(06)70538-9" @default.
- W1997993417 hasPublicationYear "2006" @default.
- W1997993417 type Work @default.
- W1997993417 sameAs 1997993417 @default.
- W1997993417 citedByCount "4" @default.
- W1997993417 countsByYear W19979934172012 @default.
- W1997993417 crossrefType "journal-article" @default.
- W1997993417 hasAuthorship W1997993417A5021521447 @default.
- W1997993417 hasAuthorship W1997993417A5028675951 @default.
- W1997993417 hasAuthorship W1997993417A5042006413 @default.
- W1997993417 hasAuthorship W1997993417A5056617646 @default.
- W1997993417 hasAuthorship W1997993417A5067312115 @default.
- W1997993417 hasConcept C121608353 @default.
- W1997993417 hasConcept C126322002 @default.
- W1997993417 hasConcept C142724271 @default.
- W1997993417 hasConcept C143998085 @default.
- W1997993417 hasConcept C193270364 @default.
- W1997993417 hasConcept C2775910329 @default.
- W1997993417 hasConcept C2776694085 @default.
- W1997993417 hasConcept C2778239845 @default.
- W1997993417 hasConcept C2780352672 @default.
- W1997993417 hasConcept C502942594 @default.
- W1997993417 hasConcept C71924100 @default.
- W1997993417 hasConcept C96232424 @default.
- W1997993417 hasConceptScore W1997993417C121608353 @default.
- W1997993417 hasConceptScore W1997993417C126322002 @default.
- W1997993417 hasConceptScore W1997993417C142724271 @default.
- W1997993417 hasConceptScore W1997993417C143998085 @default.
- W1997993417 hasConceptScore W1997993417C193270364 @default.
- W1997993417 hasConceptScore W1997993417C2775910329 @default.
- W1997993417 hasConceptScore W1997993417C2776694085 @default.
- W1997993417 hasConceptScore W1997993417C2778239845 @default.
- W1997993417 hasConceptScore W1997993417C2780352672 @default.
- W1997993417 hasConceptScore W1997993417C502942594 @default.
- W1997993417 hasConceptScore W1997993417C71924100 @default.
- W1997993417 hasConceptScore W1997993417C96232424 @default.
- W1997993417 hasIssue "12" @default.
- W1997993417 hasLocation W19979934171 @default.
- W1997993417 hasOpenAccess W1997993417 @default.
- W1997993417 hasPrimaryLocation W19979934171 @default.
- W1997993417 hasRelatedWork W2012557700 @default.
- W1997993417 hasRelatedWork W2022837219 @default.
- W1997993417 hasRelatedWork W2031494910 @default.
- W1997993417 hasRelatedWork W2342346437 @default.
- W1997993417 hasRelatedWork W2590173633 @default.
- W1997993417 hasRelatedWork W2603025253 @default.
- W1997993417 hasRelatedWork W2914146323 @default.
- W1997993417 hasRelatedWork W3032049527 @default.
- W1997993417 hasRelatedWork W3129080622 @default.
- W1997993417 hasRelatedWork W4315628570 @default.
- W1997993417 hasVolume "4" @default.
- W1997993417 isParatext "false" @default.
- W1997993417 isRetracted "false" @default.
- W1997993417 magId "1997993417" @default.
- W1997993417 workType "article" @default.